CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,286 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02727959
NCT02727959N/ACompleted

Inflammatory Bowel Disease in South Eastern Norway (IBSEN III). Clinical Epidemiology, Diagnostic and Prognostic Factors in Inflammatory Bowel Disease.

Oslo University Hospital·observational·Posted Apr 5, 2016·Updated Mar 5, 2020

In Brief

An observational study for Colitis, Ulcerative and 2 related conditions. Completed, enrolled 2,286 participants across 1 site.

Detailed Summary

The IBSEN III study will investigate the incidence of inflammatory bowel disease in South Eastern Norway and describe the clinical course of the disease. The investigators will map newly diagnosed and treatment naive IBD patients at various levels (epidemiological, clinical, psychosocial and nutritional as well as immunological, genetic, epigenetic and microbial) as a basis to improve targeted and individualized treatment and care. The investigators will include incident IBD patients at all local- and university hospitals in the South Eastern Health Region in 2016-2018 and follow-up prospectively for five years. The investigators will use standardized and validated registration methods allowing comparability with previous national and international IBD cohorts, link data to national health registries and collect blood, feces and biopsies for bio banking.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesNorway

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 5, 2016
Enrollment StartJan 1, 2017
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 10.2 years ago